• 作者：Josep Mallolas Masferrer ; ^{mallolas@clinic.ub.es} ; Marí ; a Martí ; nez-Rebollar ; Montserrat Laguno Centeno
• 关键词：Tratamiento ; Hepatitis C ; Virus de la inmunodeficiencia humana
• 刊名：Gastroenterolog铆a y Hepatolog铆a
• 出版年：2011
• 期刊代码：pca167_02105705
• 类别：med
• 出版时间：October 2011
• 卷：34
• 期：8
• 页码：558-567
• 文件大小：207 K

Hepatitis C virus (HCV)-HIV coinfection currently occurs in more than 30%of HIV-positive patients in Spain. Nowadays, the treatment of choice for chronic hepatitis due to HCV infection in HIV-positive patients is pegylated interferon plus ribavirin. This combination achieves an overall cure rate of 50%, which is somewhat lower than those obtained in patients with HCV monoinfection. Adverse effects are frequent, leading to treatment withdrawal in 10-20%of patients.

Importantly, there are three new features of hepatitis C in patients with HIV: (1) the recent development of epidemic outbreaks of acute hepatitis due to HCV infection in HIV-positive men caused by homosexual activity, (2) pharmacogenetic markers in the form of genetic polymorphisms near the IL28B gene related to response to HCV treatment as well as spontaneous eradication of HCV after acute infection, and (3) new antiviral molecules have allowed triple combination treatments to be designed and the preliminary results of clinical trials reporting high response rates are highly promising.